AstraZeneca plc 24.5% potential upside indicated by Barclays

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 24.5% according to Barclays.



Barclays set a target price of 11,000 GBX for the company, which when compared to the AstraZeneca plc share price of 8,306 GBX at opening today (02/12/2021) indicates a potential upside of 24.5%. Trading has ranged between 6,736 (52 week low) and 9,523 (52 week high) with an average of 2,073,602 shares exchanging hands daily. The market capitalisation at the time of writing is £127,926,644,960.

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.